Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim R Mocking

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Hemasphere|May 22, 2025
Applications of machine learning for immunophenotypic measurable residual disease assessment in acute myeloid leukemiaTim R Mocking, Arjan A van de Loosdrecht, Jacqueline Cloos, et al.
BMC Bioinformatics|October 23, 2025
Computationally efficient multi-sample flow cytometry data analysis using Gaussian mixture modelsPhilip Rutten, Tim R Mocking, Jacqueline Cloos, et al.
Communications Medicine|December 20, 2024
Computational assessment of measurable residual disease in acute myeloid leukemia using mixture modelsTim R Mocking, Angèle Kelder, Tom Reuvekamp, et al.
Leukemia|January 25, 2024
Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemiaJesse M Tettero, Maaike E Heidinga, Tim R Mocking, et al.
JTO Clinical and Research Reports|December 9, 2025
The Added Value of Genome-Wide Copy Numbers to Objectively Resolve Clonality of Multiple Tumors With Pulmonary Involvement and Ambiguous or Inconclusive Mutational DiagnosisJurriaan Janssen, Bárbara Andrade Barbosa, Tim R Mocking, et al.
Leukemia|February 27, 2025
CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agentsTom Reuvekamp, Lok Lam Ngai, Daphne den Hartog, et al.
Leukemia|September 3, 2025
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trialTim R Mocking, Lukas H Haaksma, Tom Reuvekamp, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Hemasphere|May 22, 2025
Applications of machine learning for immunophenotypic measurable residual disease assessment in acute myeloid leukemiaTim R Mocking, Arjan A van de Loosdrecht, Jacqueline Cloos, et al.
BMC Bioinformatics|October 23, 2025
Computationally efficient multi-sample flow cytometry data analysis using Gaussian mixture modelsPhilip Rutten, Tim R Mocking, Jacqueline Cloos, et al.
Communications Medicine|December 20, 2024
Computational assessment of measurable residual disease in acute myeloid leukemia using mixture modelsTim R Mocking, Angèle Kelder, Tom Reuvekamp, et al.
Leukemia|January 25, 2024
Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemiaJesse M Tettero, Maaike E Heidinga, Tim R Mocking, et al.
JTO Clinical and Research Reports|December 9, 2025
The Added Value of Genome-Wide Copy Numbers to Objectively Resolve Clonality of Multiple Tumors With Pulmonary Involvement and Ambiguous or Inconclusive Mutational DiagnosisJurriaan Janssen, Bárbara Andrade Barbosa, Tim R Mocking, et al.
Leukemia|February 27, 2025
CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agentsTom Reuvekamp, Lok Lam Ngai, Daphne den Hartog, et al.
Leukemia|September 3, 2025
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trialTim R Mocking, Lukas H Haaksma, Tom Reuvekamp, et al.
Pageof 1